Clinical Use of Factor IX Concentrates

Bidwell, Ethel; Rizza, CR; Dike, G. W. R.; Snape, Timothy J.

doi:10.1055/s-0038-1647986

Cited by 12 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to these reports, Grammens and Breckenridge [65] found no hypercoagulation in 2 hemophilia B patients and in 7 non-hemophiliacs who were treated with these concentrates during major sur gery. Bidwell et al [13] extended the 5-year experience report of Lane et al [93] by reporting 2 more hemophilia B patients who underwent surgery without any complica tions. They also emphasized the proper infu sion of PCC, so that prior to its entry in the circulation it does not get mixed with the intravenous fluid used for administration [48] and does not undergo activation.…”

Section: Clinical Use and Adverse Reactionsmentioning

confidence: 62%

See 1 more Smart Citation

Prothrombin Complex Concentrates for Clinical Use

Chandra¹,

Brummelhuis²

1981

Vox Sanguinis

View full text Add to dashboard Cite

Prothrombin complex concentrates prepared for clinical use are reviewed with emphasis on frequently observed adverse reactions such as viral hepatitis and thromboembolic complications. Preparation procedures and quality control are described briefly, and the use of these concentrates in the treatment of hemophilia A patients who develop factor VIII inhibitors is also described. The causes of and methods for the detection of potential thrombogenicity are discussed and suggestions which may result in a safer product are made.

show abstract

Section: Clinical Use and Adverse Reactionsmentioning

confidence: 62%

“…The treatment of congenital factor IX deficiency (Christ mas disease) has been well documented [13,15,21,54,65,71,93,94,107,111,127,135,155], and a few reports also show effective-ness in restoring hemostasis in deficiency of factors II, VII and X [79,80,114,143].…”

Section: Clinical Use and Adverse Reactionsmentioning

confidence: 99%

Prothrombin Complex Concentrates for Clinical Use

Chandra¹,

Brummelhuis²

1981

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…The product contains factor I1 and X, as well as factor IX, and has a specific factor IX activity of 2.0-3.0 idmg [17,18]. The new high-purity factor IX concentrate is prepared using a metal chelate affinity chromatography process (see page 12) and has a specific activity of 150-170 iu/mg.…”

Section: Phamacokinetic Studies In Patients With Haemophilia Bmentioning

confidence: 99%

Pharmacokinetic studies on a new purified factor IX concentrate

Thomas

1995

Haemophilia

View full text Add to dashboard Cite

Elstree, Herts. UKIn recent years, several purified factor IX concentrates have been produced with a much higher specific activity for factor IX activity than prothrombin concentrate complexes (PCCs). As a result of additional purification steps, these new concentrates are essentially free of other clotting factors [l-61. The rationale that led to the development of these products has been the hypothesis that the presence of clotting factors other than factor IX contributes to the risk of thrombogenicity previously associated with the use of PCCs [7-lo]. Recent experience with purified factor IX concentrates, both in animals and man, suggests that they may prove to be less thrombogenic than PCCs [4,11-141.The prothrombin concentrate complex produced for many years by the Bio Products Laboratory, Elstree (BPL), has a specific activity of 2.0-3.0 idmg. This product, known as 9A, has an excellent record for haemostatic efficacy, but as with other PCCs there have been occasional reports of thromboembolic complications [ 151. Accordingly, a new purified factor IX concentrate was developed by BPL that was essentially free of other clotting factors (see page 12). Following demonstrations in vitro and in animal studies that it was likely to be less thrombogenic than PCCs (see page 16), studies were carried out in man to establish the pharmacokinetic profile of the new product. Phamacokinetic studies in patients with haemophilia BA cross-over study was carried out on 19 patients with haemophilia B given on different occasions, a conventional three-factor PCC (9A) and the new high-purity factor IX (Replenine) developed by BPL [16]. Both preparations were given intravenously with at least a 7-day period between the infusions, Factor IX levels were measured pre-infusion, and at 10 and 30 min, 1, 3,6, 9,24, 30,46 and 50 h postinfusion. Sixteen severe (

show abstract

“…Corrigan37 successfully used combined EACA and factor replacement therapy in 10 haemophilic children with bleeding from the mouth not associated with dental extraction. His regimen was a single dose of cryoprecipitate (2 bags/ 10 kg body weight) followed by 41 Nevertheless, by their very nature those concentrates are potentially thrombogenic, and this must be taken into account when planning combined therapy with factor IX concentrates and inhibitors of fibrinolysis.…”

Section: Epsilon-aminocaproic Acid (Eaca)mentioning

confidence: 99%

“…Most reports of this have come from the United States and followed the use of certain commercial preparations of factor IX. 39 The factor IX concentrates made by the National Health Service fractionation laboratories seem to carry less risk of causing thromboembolism in patients with Christmas disease.40 41 Nevertheless, by their very nature those concentrates are potentially thrombogenic, and this must be taken into account when planning combined therapy with factor IX concentrates and inhibitors of fibrinolysis.…”

Section: Other Forms Of Surgerymentioning

confidence: 99%

Inhibitors of fibrinolysis in the treatment of haemophilia

Rizza¹

1980

Journal of Clinical Pathology

View full text Add to dashboard Cite

Clinical Use of Factor IX Concentrates

Cited by 12 publications

References 0 publications

Prothrombin Complex Concentrates for Clinical Use

Prothrombin Complex Concentrates for Clinical Use

Pharmacokinetic studies on a new purified factor IX concentrate

Inhibitors of fibrinolysis in the treatment of haemophilia

Contact Info

Product

Resources

About